AiCure has picked up series C capital from investors such as Singtel Innov8 and Asahi Kasei to bolster its commercial, engineering and R&D efforts.

Singtel Innov8, the corporate venturing arm of telecommunications firm Singtel, and chemicals producer Asahi Kasei yesterday backed a $24.5m series C round for US-based digital health technology provider AiCure. Palisades Growth Capital led the round, which included Accelmed Growth Partners and SpringRock Ventures, as well as Baird Capital, New Leaf Venture Partners, Pritzker Group, Biomatics…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.